- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
A proposal for rituximab treatment in patients with myasthenia gravis
-
- Konno Shingo
- Department of Neurology, Toho University Ohashi Medical Center
Bibliographic Information
- Other Title
-
- リツキシマブ治療施行経験と提言
Search this article
Description
Rituximab (RTX) is a chimeric murine/human monoclonal antibody directed against the CD20 surface antigen of B cells. RTX has been for the treatment of non-Hodikin lymphoma. Recently, RTX was shown to be effective in treating patients with myasthenia gravis (MG) who did not show improvement with other immunomodulation treatments. However, the evidence of its efficacy is mostly limited to a few case series or open-label trials. At the present stage, RTX may be permitted to be used in patients who understand the risk of its side effects and provide consent for its use in treatment. In future, it will be necessary to establish an effective and safe medication protocol of RTX in Japan.
Journal
-
- Rinsho Shinkeigaku
-
Rinsho Shinkeigaku 53 (11), 1312-1314, 2013
Societas Neurologica Japonica
- Tweet
Details 詳細情報について
-
- CRID
- 1390282680012609408
-
- NII Article ID
- 130004505428
-
- COI
- 1:STN:280:DC%2BC2c3itlynug%3D%3D
-
- ISSN
- 18820654
- 0009918X
-
- PubMed
- 24291971
-
- Text Lang
- ja
-
- Article Type
- journal article
-
- Data Source
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed
